MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Enanta Pharmaceuticals, Inc (NASDAQ: ENTA)*
Organization & Developments: Enanta
Parents
Enanta Pharmaceuticals, Inc (NASDAQ: ENTA)*
Children
*Enanta is a drug discovery company that morphs existing drugs, natural products and biologically-active peptide leads into small
2014: Enanta to get $40M upon AbbVie's filing for hepatitis C drug (2014)
2014: Enanta, No Longer Obscure, Seeks Slice of Big Hepatitis C Market (2014)
2016: Biotech Forum Daily Digest: Biotech Slowly Recovering, Analysts Line Up Behind Omeros, Spotlight On Enanta Pharmaceuticals
2019: Enanta And EDP-305 In NASH: An Update_seekingalpha.com
2023: Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch_seekingalpha.com
Jumps
*Key People: Enanta
Finance & Acquisitions: Enanta